Franklin Genomic Advancements ETF (HELX)

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that tracks companies advancing genomics and genetic science — gene-editing platforms like CRISPR, sequencing technologies, diagnostic tools, and the ecosystem of supporting businesses. It is a thematic fund: rather than holding the whole market or a broad sector, it concentrates on one technology and the companies building it.

What exactly does HELX hold?

HELX’s portfolio includes publicly traded companies across the genomics value chain: pure-play genome-editing firms, DNA-sequencing leaders, genetic diagnostic companies, and firms providing the instruments and consumables these pioneers use. Holdings span from large-cap names with market leadership to smaller, higher-growth labs and biotech startups that have gone public. The fund is reconstituted periodically as management identifies which companies are most central to advancing the field.

Because genomics is as much a platform as a single company or product, holdings cut across what might traditionally be called separate sectors — some firms are classified as biotechnology, others as medical devices or software. HELX’s screening process looks through the taxonomy and selects based on revenue and technology exposure to the underlying genomics theme. The portfolio is typically held at 40–80 holdings, giving it more focus than a broad biotech ETF but not so narrow as to be a single-stock bet.

What is the investment thesis?

The thesis is straightforward: genomics is reshaping medicine. Gene sequencing has become cheaper and faster every year, following a curve steeper than Moore’s Law. CRISPR and other editing tools are moving from laboratory proof of concepts into clinical use. Genetic diagnostics are replacing older tests. Personalized medicine — where treatment is matched to a patient’s genetic makeup — is ceasing to be experimental. These shifts are creating durable demand for the companies that supply the technology, from kit makers to software platforms interpreting the data.

Investors in HELX are betting that this transformation will continue, that the companies currently driving it will remain relevant, and that genomics will be a source of stock returns as the field matures and expands into more diseases and more markets. It is a conviction play on a specific technology, not a hedge or a way to diversify away from market risk.

How does it trade and what are the costs?

HELX trades on a major US exchange like any other stock, settling in cash, with spreads tight enough for typical retail and institutional trades. The fund itself holds US and international companies, though the majority are US-listed. The expense ratio is moderate for a thematic fund — higher than a broad-market index ETF, which costs near zero, but lower than a typical actively managed mutual fund or a hedge fund.

As with all ETFs, you pay the expense ratio annually, embedded in the net asset value. There are no hidden markups; the price you see is what you pay (or receive, if you sell). Inflows and outflows happen throughout the trading day, and the fund manager can hold a small cash position to meet redemptions without forcing sales.

What are the real risks?

Thematic funds carry distinct risks compared to broad indexes. First is concentration: HELX is not diversified across sectors or geographies. A downturn in biotech sentiment or a regulatory setback for CRISPR or gene therapy could pressure many holdings at once. You are not getting the protection of holding banks, energy, and consumer staples alongside your biotech bet.

Second is technology displacement. Gene editing is still young. CRISPR was revolutionary, but newer approaches like prime editing and base editing may eventually prove superior. A company that leads on the incumbent technology faces the risk that a newer platform emerges and takes its place — a familiar pattern in technology. Holdings in HELX are subject to the same risk that any biotech faces: development failures, failed clinical trials, missed approvals.

Third is valuation sensitivity. Thematic funds often gain popularity during periods of optimism about the underlying trend, driving valuations up. When sentiment reverses, valuations can fall sharply. Genomics stocks are often owned by growth investors and early-stage believers, meaning the fund’s holdings can be volatile in corrections.

Fourth, and worth highlighting, is regulatory risk. Gene therapy, in particular, operates under heavy scrutiny. Pricing pressure, side effects from a high-profile therapy, or changes to how gene-therapy benefits are reimbursed can affect many holdings. Companies in the HELX portfolio lobbied for and depend on specific regulatory pathways that can change.

How would a reader research this fund?

Start with the fund’s prospectus and fact sheet on the issuer’s website (Franklin Templeton), which names the selection criteria and lists the top 10 holdings. Cross-reference those names against recent news to understand what each company does. The prospectus also states whether HELX rebalances or screens out certain companies (e.g., those with inadequate market cap or liquidity), a useful detail for understanding turnover and costs.

Because genomics is a fast-moving field, a reader should pair the fund’s holding list with recent updates from the companies themselves — earnings calls, pipeline announcements, regulatory filings — to sense whether the underlying technology thesis is still intact. A fund that held CRISPR-focused stocks five years ago and holds very different ones today is normal and expected; a fund whose holdings have barely changed while the field has accelerated might be stale.

Finally, compare HELX’s performance and volatility to a broad biotech index ETF and to the overall market. Thematic funds should outperform their broad peers over long stretches if the thesis is correct, but will underperform when the theme falls out of favor. The comparison illuminates whether you are comfortable with the risk-return profile and the concentration.